The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.本揭示案提供包含細胞之針對CD19之嵌合抗原受體(CAR)遺傳修飾之自體T細胞免疫療法，其用於治療例如在二線或更多線全身性療法之後復發或難治性的大B細胞淋巴瘤，包括未特指型瀰漫性大B細胞淋巴瘤(DLBCL)、原發性縱隔大B細胞淋巴瘤、高級B細胞淋巴瘤及由濾泡性淋巴瘤引起之DLBCL。本揭示案之一些態樣係關於輸注本文所提供之T細胞療法後之治療及監測方法。
